[Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report].

ABSTRACT:

Background and objective

The significant efficacy of tyrosine kinase inhibitors (TKIs) has been approved for advanced non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations. No clear evidence exists that EGFR-L861Q is sensitive to TKIs, and the best treatment for NSCLC patients with EGFR-L861Q mutation is undetermined. This study aims to discuss the best treatment for advanced NSCLC patients with EGFR-L861Q mutation by analyzing the differences among the structures of wild-type EGFR, activating mutant EGFR-L858R, and EGFR-L861Q mutation.

Methods

The protein structures of wild-type EGFR were reconstructed. EGFR-L858R and EGFR-L861Q mutation were activated. The differences among the three kinds of protein conformation were

SUBMITTER: Wang X 

PROVIDER: S-EPMC6000112 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature